XLONCREO
Market cap97mUSD
Jan 03, Last price
19.00GBP
1D
-5.00%
1Q
-12.64%
Jan 2017
-76.66%
IPO
-76.22%
Name
Creo Medical Group PLC
Chart & Performance
P/E
—
P/S
254.25
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.26%
Rev. gr., 5y
%
Revenues
31m
+13.36%
Net income
-22m
L-19.44%
CFO
-22m
L-13.56%
Earnings
May 13, 2025
Profile
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑06 | 2017‑06 | 2016‑02 | 2015‑02 | |
| Income | ||||||||||
Revenues | 30,800 13.36% | 27,169 7.98% | ||||||||
Cost of revenue | 56,000 | 57,976 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (25,200) | (30,807) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (2,800) | (4,041) | ||||||||
Tax Rate | ||||||||||
NOPAT | (22,400) | (26,766) | ||||||||
Net income | (21,700) -19.44% | (26,936) 9.52% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 31,700 | 70 | ||||||||
BB yield | -22.02% | -0.15% | ||||||||
| Debt | ||||||||||
Debt current | 3,100 | 4,029 | ||||||||
Long-term debt | 6,600 | 6,067 | ||||||||
Deferred revenue | 1,173 | |||||||||
Other long-term liabilities | 300 | 384 | ||||||||
Net debt | (10,900) | (5,276) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (21,600) | (24,988) | ||||||||
CAPEX | (1,200) | (3,274) | ||||||||
Cash from investing activities | (18,300) | (6,027) | ||||||||
Cash from financing activities | 29,800 | 522 | ||||||||
FCF | (27,280) | (32,206) | ||||||||
| Balance | ||||||||||
Cash | 18,500 | 13,097 | ||||||||
Long term investments | 2,100 | 2,275 | ||||||||
Excess cash | 19,060 | 14,014 | ||||||||
Stockholders' equity | (121,100) | (100,113) | ||||||||
Invested Capital | 189,500 | 158,934 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 313,004 | 187,895 | ||||||||
Price | 0.46 82.18% | 0.25 -83.05% | ||||||||
Market cap | 143,982 203.48% | 47,443 -81.31% | ||||||||
EV | 133,082 | 42,167 | ||||||||
EBITDA | (21,800) | (27,694) | ||||||||
EV/EBITDA | ||||||||||
Interest | 400 | 248 | ||||||||
Interest/NOPBT | ||||||||||